2 terminated, 1 active not recruiting, 1 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
Follow ESK981: new trials by email Literature Review of ESK981 trials Research Report on ESK981
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 17 | 2024-04-19 | 2026-05-14 |
| ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 10 | 2019-11-13 | 2024-07-16 |
| Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma ESK981, Nivolumab - Renal Cell Carcinoma, Metastatic | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 8 | 2019-04-11 | 2024-05-20 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
Prostatic Neoplasms (2) · Adenoma, Islet Cell (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Renal Cell (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neoplasm Metastasis (1) · Somatostatinoma (1)
Barbara Ann Karmanos Cancer Institute (2) · University of Michigan Rogel Cancer Center (2)
United States (4)
Ajjai Alva, MD (1) · Elisabeth Heath, M.D. (1) · Elisabeth I. Heath (1) · Vaibhav Sahai (1)
P30CA022453 (2)